Meanwhile, disruption of FXR signaling has been observed in many liver diseases, including NAFLD; FXR is thus considered a promising target for the treatment of NAFLD/NASH [172,173]. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.